What's up, guys, Derek, more plates, more dates.com.

Today we're going to be talking about semaglutide.

Again, this is the premier GLP1 agonist that is the most efficacious at reaching

clinical endpoints in a diabetes management plus obesity management now aspect.

It has been presented in a format of 2.4 milligrams per week as Wegovi, dumbest name ever perhaps.

Yes, I agree.

Versus the one milligram variation, OZempic, and then obviously there's an oral iteration as well.

But that does not seem to be the best way to go.

You know, it's for people who just like really don't want to fucking inject something.

But it's ultimately going to be a lot more distress on the GI than otherwise just pinning it would be.

And it's a subcontaneous injection.

It's kind of just like pinning insulin.

However, you only have to do it once a week.

You know, very, very well-tolerated medication that has very benign slash innocuous profile

relative to other kind of, you know, weight management tools that we're more familiar with like

stimulant abuse or anything like dopaminergic agents that are going to be problematic down the line in a neurological aspect, in a cardiovascular aspect, etc.

Obviously there's other kind of like appetite suppressants out there, but ultimately GLP went G I can't fucking talk.

GLP1 Agnes from what I've seen seem to be the most promising in a, you know, benign activity aspect.

Now, are they side effect free? Of course not.

And some individuals end up, like, literally puking when they use this stuff.

However, a semi-glutide in particular, of all the GLU-P-1 Agnes,

when you compare it to dulyglutide, Lyrrugide, all of the different variants it seems to be the most efficacious like I mentioned and with the most, I don't know, it's like easiest to adhere to as well and just produces the most weight loss as well. So anyways, as well as, you know, best improvements in like glucose tolerance metrics and whatnot. But anyways, semi-glutide for weight loss has been assessed more recently at a much higher dosage variation that was otherwise presented previously for diabetes management.

...